May 25, 2017 / 10:24 AM / 2 months ago

BRIEF-RepliCel forms strategic plan for 2017-2019 focused on maturing assets

1 Min Read

May 25 (Reuters) - RepliCel Life Sciences Inc:

* RepliCel CEO provides company outlook

* RepliCel Life Sciences Inc - RepliCel continues to make significant progress on its nearest-term commercial asset, dermal injector (RCI-02)

* Replicel Life Sciences Inc - RepliCel has formulated a strategic plan for 2017 through 2019 focused on maturing its assets Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below